Healthtech start-up Enoda has launched a new platform designed to provide real-world mobility data to pharmaceutical, medtech and clinical research organisations seeking more accurate ways to measure treatment outcomes.

The company’s technology is intended to strengthen clinical trial design by generating validated mobility insights collected from patients in everyday settings rather than relying solely on traditional site-based assessments.

Mobility remains a critical indicator across conditions including Parkinson’s disease, multiple sclerosis (MS) and chronic obstructive pulmonary disease (COPD), yet capturing meaningful and consistent movement data outside clinical environments has historically presented challenges for researchers and developers.

Enoda’s platform aims to address this through an integrated Electronic Data Capture (EDC) environment that combines wearable sensing technology with digital patient monitoring and validated analytics.

The company emerged as a spin-out from University College Dublin and Newcastle University following the completion of Mobilise-D, a five-year pan-European research programme focused on improving the measurement of mobility loss in chronic disease.

Research generated through the programme has now been translated into a commercial platform intended for pharmaceutical and clinical development environments.

According to Enoda, the platform has undergone both technical and clinical validation across multiple patient cohorts and disease areas to establish the reliability of mobility measurement outputs.

The solution incorporates digital mobility outcomes intended to provide researchers with additional insight into disease progression, treatment response and patient function in real-world conditions.

The company believes these capabilities could support wider adoption of decentralised and hybrid clinical trial models while helping sponsors improve data quality and generate stronger evidence during development programmes.

For pharmaceutical organisations, the growing use of real-world evidence and digital endpoints is becoming increasingly important as developers seek more patient-centred approaches to evaluating therapies and demonstrating value beyond controlled clinical environments.

Read more about Enoda’s mobility platform and real-world clinical trial innovation in the original report.